Showing results (111-120 of 122) with videos related to
Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2022
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed GlioblastomaManmeet S Ahluwalia, David A Reardon, Ajay P Abad, et al.Neurology|December 21, 2014
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningiomaAndrew D Norden, Keith L Ligon, Samantha N Hammond, et al.Future Oncology (London, England)|December 7, 2023
Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patientsIan Y Lee, Simon Hanft, Michael Schulder, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2015
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma PatientsEudocia Q Lee, Thomas J Kaley, Dan G Duda, et al.Cell Reports|July 26, 2018
The ESCRT-III Protein CHMP1A Mediates Secretion of Sonic Hedgehog on a Distinctive Subtype of Extracellular VesiclesMichael E Coulter, Cristina M Dorobantu, Gerrald A Lodewijk, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2025
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 AstrocytomaHoward Colman, Giuseppe Lombardi, Eric T Wong, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2024
Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent GlioblastomaFabio M Iwamoto, Shyam K Tanguturi, Lakshmi Nayak, et al.European Journal of Cancer (Oxford, England : 1990)|May 22, 2012
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modalityRoger Stupp, Eric T Wong, Andrew A Kanner, et al.Cancer Drug Resistance (Alhambra, Calif.)|June 13, 2025
Acquired resistance to molecularly targeted therapies for cancerNolan M Stubbs, Tyler J Roady, Maximilian P Schwermann, et al.JCO Precision Oncology|September 14, 2020
Exploring Predictors of Response to Dacomitinib in <i>EGFR</i>-Amplified Recurrent GlioblastomaAndrew S Chi, Daniel P Cahill, David A Reardon, et al.Pageof 13